Stay updated with breaking news from Daniel Menold. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CymaBay Therapeutics (NASDAQ:CBAY – Free Report) had its price target increased by Jonestrading from $13.00 to $15.00 in a research report report published on Tuesday, Benzinga reports. Jonestrading currently has a buy rating on the biopharmaceutical company’s stock. CBAY has been the subject of several other research reports. Guggenheim began coverage on shares of CymaBay […]
CymaBay Therapeutics (NASDAQ:CBAY – Free Report) had its price target raised by BTIG Research from $18.00 to $22.00 in a research report sent to investors on Friday, MarketBeat reports. BTIG Research currently has a buy rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently issued reports on CBAY. Guggenheim initiated coverage […]
HC Wainwright reiterated their buy rating on shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) in a research report report published on Thursday, Benzinga reports. The firm currently has a $19.00 target price on the biopharmaceutical company’s stock. Other research analysts also recently issued reports about the stock. StockNews.com downgraded shares of CymaBay Therapeutics from […]
Stock analysts at Guggenheim assumed coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report) in a research report issued to clients and investors on Friday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $20.00 price target on the biopharmaceutical company’s stock. Guggenheim’s price objective would suggest a potential upside of […]
CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report) had its price objective raised by analysts at BTIG Research from $18.00 to $22.00 in a report released on Friday, Marketbeat reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. BTIG Research’s target price would suggest a potential upside of 63.33% from the stock’s […]